Skip to content

A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia

A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01232790
Acronym
NAC
Enrollment
28
Registered
2010-11-02
Start date
2010-02-28
Completion date
2011-11-30
Last updated
2015-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Schizophrenia, working memory, N-Acetylcysteine

Brief summary

The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.

Detailed description

Working memory impairment in Schizophrenia is produced by deficiencies of feedback inhibition of glutamate release, due to low cysteine-glutamate antiporter activity. Because of this mechanism, we are interested in whether acute administration of N-Acetylcysteine will improve performance of patients with schizophrenia on a battery of cognitive tasks utilized to test working memory and other cognitive domains, versus placebo. This pilot study will utilize a randomized, double blind, placebo controlled, crossover design.

Interventions

DIETARY_SUPPLEMENTN-Acetylcysteine

N-acetylcysteine 1200mg bid for 3 days

DRUGPlacebo

Placebo

Sponsors

National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Subjects will be between 18-60 * Meet Diagnostic and Statistical Manual-IV (DSM) criteria for schizophrenia * Be on a stable dose of antipsychotic medication for at least 1 month * Be deemed clinically stable for 3 months by the regular clinical staff

Exclusion criteria

* Current substance or alcohol abuse * Pregnancy * Clozapine treatment * Known sensitivity to sulphur containing compounds * Previous diagnosis of mental retardation * Nitroglycerin use * Asthma diagnosis, verified and treated by a primary care doctor * Use of any other medication that may interact with the study medication

Design outcomes

Primary

MeasureTime frameDescription
BACS Composite RAW ScoreBaselineThe Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Secondary

MeasureTime frameDescription
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.BaselineLetter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Brief Visuospatial Memory Test (BVMT) RAW SCORE.BaselineBrief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Brief Psychiatric Rating Scale (BPRS)Total ScorePre ScreeningBrief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.

Countries

United States

Participant flow

Participants by arm

ArmCount
Participants
This is the overall group of trial participants prior to randomization to either of the two crossover arms in the study.
28
Total28

Withdrawals & dropouts

PeriodReasonFG000FG001
First CrossoverWithdrawal by Subject10
Initial AssessmentWithdrawal by Subject01
RandomizationPhysician Decision01
RandomizationProtocol Violation01
RandomizationWithdrawal by Subject20
Second CrossoverWithdrawal by Subject12

Baseline characteristics

CharacteristicParticipants
Age, Continuous48.64 years
STANDARD_DEVIATION 10.58
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
20 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
4 / 116 / 124 / 114 / 11
serious
Total, serious adverse events
0 / 110 / 120 / 110 / 11

Outcome results

Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Follow Up 1st Leg of Crossover (5 Days)

Population: Per protocol

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score231.58 units on a scaleStandard Deviation 43.25
PlaceboBACS Composite RAW Score237.00 units on a scaleStandard Deviation 37.62
Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Follow Up (5 days)

Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score234.90 units on a scaleStandard Deviation 35.15
PlaceboBACS Composite RAW Score237.77 units on a scaleStandard Deviation 41.37
Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Change from Baseline at Follow Up (5 days)

Population: Subjects analyzed are only those with complete data at baseline and 5 day follow up in the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score-7.00 units on a scaleStandard Deviation 13.89
PlaceboBACS Composite RAW Score-5.59 units on a scaleStandard Deviation 13.63
Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Baseline 1st Leg of Crossover

Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score222.75 units on a scaleStandard Deviation 40.72
PlaceboBACS Composite RAW Score226.45 units on a scaleStandard Deviation 34.73
Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Baseline

Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score229.04 units on a scaleStandard Deviation 38.95
PlaceboBACS Composite RAW Score227.83 units on a scaleStandard Deviation 44.44
Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Follow Up 2nd Leg of Crossover (5 Days)

Population: Subjects analyzed are those with complete data at follow up and does not include those dropped out from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score238.55 units on a scaleStandard Deviation 46.67
PlaceboBACS Composite RAW Score239.33 units on a scaleStandard Deviation 21.85
Primary

BACS Composite RAW Score

The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.

Time frame: Baseline 2nd Leg of Crossover

Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBACS Composite RAW Score229.08 units on a scaleStandard Deviation 53.38
PlaceboBACS Composite RAW Score235.91 units on a scaleStandard Deviation 239.33
Secondary

Brief Psychiatric Rating Scale (BPRS)Total Score

Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.

Time frame: Change from PreScreening at End of Trial

Population: Analyses only used matched cases and does not include participants with incomplete data.

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Psychiatric Rating Scale (BPRS)Total Score1.70 units on a scaleStandard Deviation 2.36
PlaceboBrief Psychiatric Rating Scale (BPRS)Total Score0.89 units on a scaleStandard Deviation 1.05
Secondary

Brief Psychiatric Rating Scale (BPRS)Total Score

Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.

Time frame: Pre Screening

Population: Per protocol

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Psychiatric Rating Scale (BPRS)Total Score30.92 units on a scaleStandard Deviation 7.2
PlaceboBrief Psychiatric Rating Scale (BPRS)Total Score28.41 units on a scaleStandard Deviation 7.41
Secondary

Brief Psychiatric Rating Scale (BPRS)Total Score

Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.

Time frame: End of Trial

Population: Per protocol

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Psychiatric Rating Scale (BPRS)Total Score32.80 units on a scaleStandard Deviation 7.31
PlaceboBrief Psychiatric Rating Scale (BPRS)Total Score27.78 units on a scaleStandard Deviation 8.91
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Baseline

Population: All participants were analyzed that had baseline data collected (including any that did not complete the time frame).

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.20.35 units on a scaleStandard Deviation 6.29
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.20.65 units on a scaleStandard Deviation 7.87
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Follow Up 1st Leg of Crossover (5 Days)

Population: Per protocol

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.16.55 units on a scaleStandard Deviation 6.07
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.18.25 units on a scaleStandard Deviation 7.39
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Baseline 2nd Leg of Crossover

Population: Subjects analyzed are those with complete data at 2nd baseline in the crossover and could include those that had dropped from the study if data was collected prior to drop out.

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.21.50 units on a scaleStandard Deviation 7.8
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.20.00 units on a scaleStandard Deviation 7.01
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Follow Up 2nd Leg of Crossover (5 Days)

Population: Per protocol

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.18.82 units on a scaleStandard Deviation 5.69
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.17.44 units on a scaleStandard Deviation 4.85
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Change from Baseline at Follow Up (Baseline - Follow Up)

Population: Subjects analyzed are those with complete data at all timepoints and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.2.57 units on a scaleStandard Deviation 5.13
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.2.77 units on a scaleStandard Deviation 5.76
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Baseline 1st Leg of Crossover

Population: Per protocol

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.20.67 units on a scaleStandard Deviation 5.82
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.19.73 units on a scaleStandard Deviation 16.55
Secondary

Brief Visuospatial Memory Test (BVMT) RAW SCORE.

Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.

Time frame: Follow Up (5 days)

Population: Subjects analyzed are those with complete data at follow up in the crossover and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionBrief Visuospatial Memory Test (BVMT) RAW SCORE.17.90 units on a scaleStandard Deviation 6.29
PlaceboBrief Visuospatial Memory Test (BVMT) RAW SCORE.17.68 units on a scaleStandard Deviation 5.86
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Baseline 2nd Leg of Crossover

Population: Subjects analyzed are those with complete data at 2nd baseline in the crossover and could include those that had dropped from the study if data was collected prior to drop out.

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.42 units on a scaleStandard Deviation 3.08
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.55 units on a scaleStandard Deviation 2.81
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Baseline 1st Leg of Crossover

Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.33 units on a scaleStandard Deviation 2.84
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.00 units on a scaleStandard Deviation 3.35
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Change from Baseline at Follow Up (5 days)

Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.0.14 units on a scaleStandard Deviation 1.82
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.-0.45 units on a scaleStandard Deviation 2.36
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Follow Up (5 days)

Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.48 units on a scaleStandard Deviation 3.15
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.81 units on a scaleStandard Deviation 3.49
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Baseline

Population: All participants were analyzed that had baseline data collected (including any that did not complete the time frame).

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.43 units on a scaleStandard Deviation 2.76
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.22 units on a scaleStandard Deviation 3.15
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Follow Up 1st Leg of Crossover (5 Days)

Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.12.75 units on a scaleStandard Deviation 2.41
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.13.36 units on a scaleStandard Deviation 3.67
Secondary

Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.

Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.

Time frame: Follow Up 2nd Leg of Crossover (5 Days)

Population: Subjects analyzed are those with complete data at 2nd follow up in the crossover and does not include those that had dropped from the study.

ArmMeasureValue (MEAN)Dispersion
InterventionLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.14.27 units on a scaleStandard Deviation 3.41
PlaceboLetter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.14.44 units on a scaleStandard Deviation 1.51

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026